(Rac) -Vazegepant-13C, d3
(Rac) -Vazegepant-13C, d3 is the C13 and deuterium labeled (Rac) -Vazegepant. Vazegepant is the first intranasal CGRP receptor antagonist for the study the acute research of migraine[1][2].
Product Specifications
UNSPSC
12352005
Target
Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Others
Field of Research
Others
Solubility
10 mM in DMSO
Smiles
CC1=C2NN=CC2=CC(CC(NC(N3CCC(C4=CC5=CC=CC=C5NC4=O)CC3)=O)C(N6CCN(C7CCN([13C]([2H])([2H])[2H])CC7)CC6)=O)=C1
Molecular Formula
C35 13CH43D3N8O3
Molecular Weight
642.81
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Leonard KA, et al. Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2020 Mar 26;63 (6) :2915-2929.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC680304-100 1x 100 µL
CD106 / VCAM1 (B-K9), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880146-500 1x 500 µL
CD10 (CB-CALLA), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400178-100 1x 100 µL
CD50 (ICAM-3) (186-2G9), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401188-100 1x 100 µL
SUMO-1 (SUMO1/1188), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details